CDMRP TBIPH Clinical Trial Award

Funding to support the rapid implementation of clinical trials with the potential to have a significant impact on traumatic brain injury (TBI) and/or psychological health through clinical applications, including healthcare products, technologies, and/or clinical practice guidelines.

The US Department of Defense (DoD) Congressionally Directed Medical Research Program (CDMRP) was established in 1992 and is one of the largest funders of clinical research in the United States. CDMRP aims to foster novel approaches to biomedical research in response to the expressed needs of its stakeholders (the American public, the U.S military, and Congress). CDMRP fulfils this mission by funding high impact, high risk and high gain projects that other agencies may not venture to fund. This is why all of the programmes managed by CDMRP share the common goal of advancing paradigm shifting research, solutions that will lead to cures or improvements in patient care, or breakthrough technologies and resources for clinical benefit.

The aim of the CDMRP Traumatic Brain Injury and Psychological Health Program (TBIPHRP) is to support research to understand, prevent and treat traumatic brain injury and psychological health conditions that accelerates solutions to improve health and healthcare of Service Members, DOD beneficiaries, Veterans, and the American public.

The CDMRP TBIPHRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on traumatic brain injury (TBI) and/or psychological health through clinical applications, including healthcare products, technologies, and/or clinical practice guidelines.

Research must address at least one of the focus areas.

Different research levels are available:

• Research Level 1: Proof-of-principle pilot trials, correlative studies, and other innovative, exploratory clinical trials (Early-Career Investigator Partnering Option is available).
• Research Level 2: Clinical trials for promising treatments or interventions that have already demonstrated acceptable safety in human subjects.
• Research Level 3: Large-scale clinical trials to demonstrate efficacy in relevant patient populations.

Community-Based Participatory Research (CBPR) approaches are required.